"Researchers hope that European manufacturers will be able to take delivery of candidate vaccine prototypes in the coming months so preliminary steps to mass vaccine production can begin, " the statement said.
This means the subscription revenue that had been building as backlog for the past four quarters will finally begin to hit the income statement and that ACCL will likely crush year-over-year comparisons in the current quarter (ending March 31, 2005).